CD8A and neoplasm: This is important from the point of view that administration of non-targeted .NO donors in vivo, in addition to targeting tumor cells, it may also affect anti-tumor T cells (CD4 and CD8), the outcome of which may or may not be highly beneficial in the eradication of the tumor.